The transcription factor SPDEF suppresses prostate tumor metastasis

Journal of Biological Chemistry

Volumn 287, Issue 35, 2012, Pages 29968-29978

  Steffan, Joshua J ^a,b   Koul, Sweaty ^a,b   Meacham, Randall B ^a   Koul, Hari K ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MIGRATION; EPITHELIAL-MESENCHYMAL TRANSITION; ETS TRANSCRIPTION FACTOR; IN-VITRO; IN-VIVO; OVARIAN CANCERS; PROSTATE CANCER CELLS; PROSTATE TUMOR; STABLE EXPRESSION; SUBCUTANEOUS TUMOR; TRANSCRIPTIONAL ANALYSIS; TUMOR CELLS; TUMOR INVASION; TUMOR METASTASIS; TUMORIGENESIS;

CELL GROWTH; CELLS; CYTOLOGY; DISEASES; GENES; GROWTH KINETICS; PATHOLOGY; TRANSCRIPTION FACTORS; UROLOGY;

TUMORS;

COLLAGENASE 3; GELATINASE B; SAM POINTED DOMAIN CONTAINING ETS TRANSCRIPTION FACTOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865451304     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.379396     Document Type: Article

References (44)

1. Hanahan, D., and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70
2. Chambers, A. F., Groom, A. C., and MacDonald, I. C. (2002) Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572
3. Naumov, G. N., MacDonald, I. C., Chambers, A. F., and Groom, A. C. (2001) Solitary cancer cells as a possible source of tumour dormancy? Semin. Cancer Biol. 11, 271-276
4. Naumov, G. N., MacDonald, I. C., Weinmeister, P. M., Kerkvliet, N., Nadkarni, K. V., Wilson, S. M., Morris, V. L., Groom, A. C., and Chambers, A. F. (2002) Persistence of solitary mammary carcinoma cells in a secondary site. Cancer Res. 62, 2162-2168
5. Sharrocks, A. D. (2001) The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2, 827-837
6. Steffan, J. J., and Koul, H. K. (2011) Prostate-derived ETS factor (PDEF): A putative tumor metastasis suppressor. Cancer Lett. 310, 109-117
7. Sood, A. K., Kim, H., and Geradts, J. (2012) PDEF in prostate cancer. Prostate 72, 592-596
8. Turner, D. P., Moussa, O., Sauane, M., Fisher, P. B., and Watson, D. K. (2007) Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res. 67, 1618-1625
9. Gunawardane, R. N., Sgroi, D. C., Wrobel, C. N., Koh, E., Daley, G. Q., and Brugge, J. S. (2005) Novel role for PDEF in epithelial cell migration and invasion. Cancer Res. 65, 11572-11580
10. Schaefer, J. S., Sabherwal, Y., Shi, H. Y., Sriraman, V., Richards, J., Minella, A., Turner, D. P., Watson, D. K., and Zhang, M. (2010) Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. J. Biol. Chem. 285, 11258-11269
11. Ghosh, S., Basu, M., and Roy, S. S. (2012) ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J. Biol. Chem. 287, 15001-15015
12. Johnson, T. R., Koul, S., Kumar, B., Khandrika, L., Venezia, S., Maroni, P. D., Meacham, R. B., and Koul, H. K. (2010) Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF. Mol Cancer 9, 148
13. Sood, A. K., Saxena, R., Groth, J., Desouki, M. M., Cheewakriangkrai, C., Rodabaugh, K. J., Kasyapa, C. S., and Geradts, J. (2007) Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum. Pathol. 38, 1628-1638
14. Tsujimoto, Y., Nonomura, N., Takayama, H., Yomogida, K., Nozawa, M., Nishimura, K., Okuyama, A., Nozaki, M., and Aozasa, K. (2002) Utility of immunohistochemical detection of prostate-specific Ets for the diagnosis of benign and malignant prostatic epithelial lesions. Int. J. Urol. 9, 167-172
15. Ghadersohi, A., Sharma, S., Zhang, S., Azrak, R. G., Wilding, G. E., Manjili, M. H., and Li, F. (2011) Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate 71, 1178-1188
16. Bodenstine, T. M., and Welch, D. R. (2008) Metastasis suppressors and the tumor microenvironment. Cancer Microenviron. 1, 1-11
17. Alix-Panabières, C., Riethdorf, S., and Pantel, K. (2008) Circulating tumor cells and bone marrow micrometastasis. Clin. Cancer Res. 14, 5013-5021
18. van Kempen, L. C., and Coussens, L. M. (2002) MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2, 251-252
19. Deryugina, E. I., and Quigley, J. P. (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25, 9-34
20. Itoh, T., Tanioka, M., Matsuda, H., Nishimoto, H., Yoshioka, T., Suzuki, R., and Uehira, M. (1999) Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis 17, 177-181
21. Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., Senior, R. M., and Shibuya, M. (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2, 289-300
22. Cazorla, M., Hernández, L., Nadal, A., Balbín, M., López, J. M., Vizoso, F., Fernández, P. L., Iwata, K., Cardesa, A., López-Otín, C., and Campo, E. (1998) Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx. J. Pathol. 186, 144-150
23. Feldman, R. J., Sementchenko, V. I., Gayed, M., Fraig, M. M., and Watson, D. K. (2003) Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res. 63, 4626-4631
24. Turner, D. P., Findlay, V. J., Moussa, O., Semenchenko, V. I., Watson, P. M., LaRue, A. C., Desouki, M. M., Fraig, M., and Watson, D. K. (2011) Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate 71, 1723-1735
25. + Exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic 10, 737-753
26. Kumar, B., Koul, S., Khandrika, L., Meacham, R. B., and Koul, H. K. (2008) Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 68, 1777-1785
27. Steffan, J. J., and Cardelli, J. A. (2010) Thiazolidinediones induce Rab7-RILP-MAPK-dependent juxtanuclear lysosome aggregation and reduce tumor cell invasion. Traffic 11, 274-286
28. Findlay, V. J., Turner, D. P., Yordy, J. S., McCarragher, B., Shriver, M. R., Szalai, G., Watson, P. M., Larue, A. C., Moussa, O., and Watson, D. K. (2011) Prostate-derived ETS factor regulates epithelial-to-mesenchymal transition through both SLUG-dependent and independent mechanisms. Genes Cancer 2, 120-129
29. Moss, N. M., Liu, Y., Johnson, J. J., Debiase, P., Jones, J., Hudson, L. G., Munshi, H. G., and Stack, M. S. (2009) Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol. Cancer Res. 7, 809-820
30. Oettgen, P., Finger, E., Sun, Z., Akbarali, Y., Thamrongsak, U., Boltax, J., Grall, F., Dube, A., Weiss, A., Brown, L., Quinn, G., Kas, K., Endress, G., Kunsch, C., and Libermann, T. A. (2000) PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J. Biol. Chem. 275, 1216-1225
31. Ghadersohi, A., and Sood, A. K. (2001) Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin. Cancer Res. 7, 2731-2738
32. Ghadersohi, A., Odunsi, K., Zhang, S., Azrak, R. G., Bundy, B. N., Manjili, M. H., and Li, F. (2008) Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int. J. Cancer 123, 1376-1384
33. Rodabaugh, K. J., Mhawech-Fauceglia, P., Groth, J., Lele, S., and Sood, A. (2007) Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors. Int. J. Gynecol. Pathol. 26, 10-15
34. Moussa, O., Turner, D. P., Feldman, R. J., Sementchenko, V. I., McCarragher, B. D., Desouki, M. M., Fraig, M., and Watson, D. K. (2009) PDEF is a negative regulator of colon cancer cell growth and migration. J. Cell Biochem. 108, 1389-1398
35. Liu, Z., Li, L., Yang, Z., Luo, W., Li, X., Yang, H., Yao, K., Wu, B., and Fang, W. (2010) Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer 10, 270
36. Bendardaf, R., Buhmeida, A., Hilska, M., Laato, M., Syrjänen, S., Syrjänen, K., Collan, Y., and Pyrhönen, S. (2010) MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest. 28, 38-43
37. Tian, M., Cui, Y. Z., Song, G. H., Zong, M. J., Zhou, X. Y., Chen, Y., and Han, J. X. (2008) Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8, 241
38. Zhao, Z. S., Wang, Y. Y., Ye, Z. Y., and Tao, H. Q. (2009) Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol. Oncol. Res. 15, 589-596
39. Provatopoulou, X., Gounaris, A., Kalogera, E., Zagouri, F., Flessas, I., Goussetis, E., Nonni, A., Papassotiriou, I., and Zografos, G. (2009) Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 9, 390
40. Castellano, G., Malaponte, G., Mazzarino, M. C., Figini, M., Marchese, F., Gangemi, P., Travali, S., Stivala, F., Canevari, S., and Libra, M. (2008) Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin. Cancer Res. 14, 7470-7480
41. Zhang, L., Shi, J., Feng, J., Klocker, H., Lee, C., and Zhang, J. (2004) Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis. 7, 327-332
42. Chambers, A. F., and Matrisian, L. M. (1997) Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89, 1260-1270
43. Sehgal, G., Hua, J., Bernhard, E. J., Sehgal, I., Thompson, T. C., and Muschel, R. J. (1998) Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am. J. Pathol. 152, 591-596
44. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737-744